551 related articles for article (PubMed ID: 28821272)
21. Antibody therapy for acute lymphoblastic leukemia.
Portell CA; Advani AS
Curr Hematol Malig Rep; 2012 Jun; 7(2):153-9. PubMed ID: 22422550
[TBL] [Abstract][Full Text] [Related]
22. CD19-targeted immunotherapies for treatment of patients with non-Hodgkin B-cell lymphomas.
Watkins MP; Bartlett NL
Expert Opin Investig Drugs; 2018 Jul; 27(7):601-611. PubMed ID: 29940805
[TBL] [Abstract][Full Text] [Related]
23. Targeting CD22 in B-cell malignancies: current status and clinical outlook.
Sullivan-Chang L; O'Donnell RT; Tuscano JM
BioDrugs; 2013 Aug; 27(4):293-304. PubMed ID: 23696252
[TBL] [Abstract][Full Text] [Related]
24. Immunotherapy in indolent Non-Hodgkin's Lymphoma.
Amhaz G; Bazarbachi A; El-Cheikh J
Leuk Res Rep; 2022; 17():100325. PubMed ID: 35663281
[TBL] [Abstract][Full Text] [Related]
25. Nanobody-based anti-CD22-chimeric antigen receptor T cell immunotherapy exhibits improved remission against B-cell acute lymphoblastic leukemia.
Zhang T; Wang T; You F; Li Z; Chen D; Zhang K; Tian S; Sheng B; Wu H; Jiang L; Ma R; An G; Meng H; Yang L
Transpl Immunol; 2022 Apr; 71():101538. PubMed ID: 35051588
[TBL] [Abstract][Full Text] [Related]
26. Current status of antibody therapy in ALL.
Ai J; Advani A
Br J Haematol; 2015 Feb; 168(4):471-80. PubMed ID: 25382151
[TBL] [Abstract][Full Text] [Related]
27. Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma.
Aujla A; Aujla R; Liu D
Biomark Res; 2019; 7():9. PubMed ID: 31011424
[TBL] [Abstract][Full Text] [Related]
28. Debate: Transplant Is Still Necessary in the Era of Targeted Cellular Therapy for Acute Lymphoblastic Leukemia.
Khazal S; Kebriaei P
Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):713-719. PubMed ID: 32694050
[TBL] [Abstract][Full Text] [Related]
29. Management of adverse effects of new monoclonal antibody treatments in acute lymphoblastic leukemia.
Conde-Royo D; Juárez-Salcedo LM; Dalia S
Drugs Context; 2020; 9():. PubMed ID: 33110433
[TBL] [Abstract][Full Text] [Related]
30. Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens: Monoclonal Antibodies, Immune Checkpoint Inhibitors and CAR T-Cell Therapies.
Kyriakidis I; Vasileiou E; Rossig C; Roilides E; Groll AH; Tragiannidis A
J Fungi (Basel); 2021 Mar; 7(3):. PubMed ID: 33807678
[TBL] [Abstract][Full Text] [Related]
31. Monoclonal antibodies in acute lymphoblastic leukemia.
Jabbour E; O'Brien S; Ravandi F; Kantarjian H
Blood; 2015 Jun; 125(26):4010-6. PubMed ID: 25999456
[TBL] [Abstract][Full Text] [Related]
32. Chemoimmunotherapy in acute lymphoblastic leukemia.
Hoelzer D; Gökbuget N
Blood Rev; 2012 Jan; 26(1):25-32. PubMed ID: 21958552
[TBL] [Abstract][Full Text] [Related]
33. Using immunotherapy and novel trial designs to optimise front-line therapy in adult acute lymphoblastic leukaemia: breaking with the traditions of the past.
Short NJ; Kantarjian H
Lancet Haematol; 2023 May; 10(5):e382-e388. PubMed ID: 37003279
[TBL] [Abstract][Full Text] [Related]
34. Inotuzumab ozogamicin: a CD22 mAb-drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Yurkiewicz IR; Muffly L; Liedtke M
Drug Des Devel Ther; 2018; 12():2293-2300. PubMed ID: 30087554
[TBL] [Abstract][Full Text] [Related]
35. Novel immunotherapies in lymphoid malignancies.
Batlevi CL; Matsuki E; Brentjens RJ; Younes A
Nat Rev Clin Oncol; 2016 Jan; 13(1):25-40. PubMed ID: 26525683
[TBL] [Abstract][Full Text] [Related]
36. SOHO State of the Art Update and Next Questions: Advances in the Treatment of Adult Acute Lymphoblastic Leukemia.
Paul S; Rausch CR; Welch MA; Kantarjian HM; Jabbour EJ
Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):471-479. PubMed ID: 31307896
[TBL] [Abstract][Full Text] [Related]
37. Preclinical characterization and comparison between CD3/CD19 bispecific and novel CD3/CD19/CD20 trispecific antibodies against B-cell acute lymphoblastic leukemia: targeted immunotherapy for acute lymphoblastic leukemia.
Wang S; Peng L; Xu W; Zhou Y; Zhu Z; Kong Y; Leung S; Wang J; Yan X; Mi JQ
Front Med; 2022 Feb; 16(1):139-149. PubMed ID: 34463907
[TBL] [Abstract][Full Text] [Related]
38. Novel Therapeutic Strategies in Acute Lymphoblastic Leukemia.
Dias A; Kenderian SJ; Westin GF; Litzow MR
Curr Hematol Malig Rep; 2016 Aug; 11(4):253-64. PubMed ID: 27101015
[TBL] [Abstract][Full Text] [Related]
39. Moving immunotherapy into the front line in ALL.
Winters A; Gore L
Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):209-217. PubMed ID: 31808875
[TBL] [Abstract][Full Text] [Related]
40. Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia.
Liu D; Zhao J; Song Y; Luo X; Yang T
J Hematol Oncol; 2019 Feb; 12(1):15. PubMed ID: 30736842
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
